Novigenix is a precision medicine company that specializes in ImmunoTranscriptomic solutions.

Sign up today and learn more about NOVIGENIX Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.


Novigenix is a Swiss precision medicine company specialized in ImmunoTranscriptomic solutions for the detection of disease, therapy optimization, and disease recurrence monitoring to improve disease management and patient outcomes. The Novigenix proprietary LITOseek platform is optimized for mapping the response of the immune system to onset and progression of disease by integrating patient multi-omics data, advanced Machine Learning, and artificial intelligence approaches, to provide actionable insights and precision solutions for optimization of patient’s therapeutic journey. Our product pipeline currently includes patient stratification solutions in the field of Immuno-Oncology, Colorectal Cancer early detection and recurrence monitoring, and therapy optimization solutions for management of cancer patients. Novigenix provides services to Pharma and Biotech customers by leveraging the proprietary LITOseek data analytics and patient clinical data platform to deliver previously unknown insights into the immune system, and develop ImmunoTranscriptomic solutions with actionable biomarkers for optimization of new therapeutic modalities.

Funding History

January 2020$1.0M
November 2022$20.0M


Co-Founder and Director Scientific and Clinical Affairs

Laura Ciarloni

Executive Chairman

Brian Hashemi

Chief Technology Officer, Co-Founder

Sahar Hosseinian


Christian Jauch

Co-Founder and Director of Technology Development

Sylvain Monnier Benoit

Non-Executive Director of the Board

Jan Groen

President and CBO

Valentin Matillon


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: